Daiichi Sankyo and AstraZeneca’s Enhertu has been approved in the European Union, or EU, as monotherapy indicated for the treatment of adult patients with unresectable or metastatic HER2 low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- Novartis downgraded to Neutral from Buy at Citi
- Thermo Fisher, AstraZeneca team on CDx test for Tagrisso
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- AstraZeneca commences tender offer to acquire CinCor Pharma for $26.00 per share
- Biotech Alert: Searches spiking for these stocks today